GSK Will Pay Up to $1.5 Billion for CureVac's MRNA Vaccines -- Barrons.com
By Josh Nathan-Kazis The drugmaker GSK plunged into the messenger RNA-based vaccine market Wednesday, announcing it will buy the rights to experimental influenza and Covid-19 mRNA vaccines from the b
Pfizer (PFE) Stock Falls in a Year: Time to Buy, Sell or Hold?
GSK Buys Full Rights To Investigational Covid-19 And Influenza Vaccines From CureVac For Around $1.5B
Wednesday, GSK plc (NYSE:GSK) and CureVac N.V. (NASDAQ:CVAC) announced they have restructured their existing collaboration into a new licensing agreement, allowing the companies to prioritize investme
Update: Market Chatter: Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits
(Updates with statement from GSK in fourth and fifth paragraphs.) A Delaware Superior Court judge rejected an appeal from GSK (GSK) and other drugmakers to overturn a ruling that cleared the way for o
After falling to an 11-year low and consolidating for several months, should I buy or sell pfizer (PFE.US) now?
In April of this year, Pfizer (PFE.US) stock price fell to its lowest point since January 2013. As of the closing price on July 1, the stock has risen by about 11% since then; After falling to an 11-year low, Pfizer has been consolidating for several months. So, should you buy or sell Pfizer stocks now? From a fundamental perspective, Pfizer is still trying to overcome the drag from the cooling of its COVID-19 products and actively promote the development of non-COVID-19 drug business. Recently, the company announced positive trial results of two potential anticancer drugs, but also closed a gene therapy project, and the company's stock price continues to trade sideways. In a study, patients who received Pfizer Elrex
Pfizer Options Spot-On: On July 2nd, 90,664 Contracts Were Traded, With 2.74 Million Open Interest
On July 2nd ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 90,664 options for the day, of which put options accounted for 49.39% of the total transactions, and call op
Atopic Dermatitis Market to Register Incremental Growth by 2034, Examines DelveInsight | Key Companies - Arcutis Biotherapeutics, Amgen, Kyowa Kirin, Dermavant Sciences, Cara Therapeutics, Pfizer, Arena Pharmaceuticals
New York, USA, July 02, 2024 (GLOBE NEWSWIRE) -- Atopic Dermatitis Market to Register Incremental Growth by 2034, Examines DelveInsight | Key Companies - Arcutis Biotherapeutics, Amgen, Kyowa Kirin, Dermavant
COVID Infections Could Be Seeing a Summer Surge Based on CDC Data
Unusual Options Activity: CRH, CPNG and Others Attract Market Bets, CRH V/OI Ratio Reaches 312.5
EST Jul 2nd Morning Delivery - In the last two hours of trading, 7 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.Of
Pfizer-BioNTech, Moderna Set to Appeal Mixed UK Ruling in COVID-19 Vaccine Patent Case
Moderna (0QF.F) and its rivals Pfizer (PFE.F) and BioNTech (22UA.F) are considering appeals after London's High Court handed down a mixed ruling in their patent dispute relating to the mRNA technology
Heartburn Drug Zantac Litigation: GSK And Other Pharma Giants Face Trial Over Cancer Claims
A Delaware judge has dismissed a request from GSK Plc (NYSE:GSK) and other pharmaceutical companies to appeal a ruling that allows over 70,000 lawsuits alleging the heartburn drug Zantac causes cancer
Moderna Gets $176 Million From the U.S. to Make a Bird Flu Vaccine -- Barrons.com
By Josh Nathan-Kazis The drugmaker Moderna said Tuesday that it had received $176 million from the U.S. government to develop a messenger-RNA based bird flu vaccine for humans. The award, made throu
Pfizer Vs Moderna Covid Vaccine Patents Battle Set to Continue
Pfizer and Moderna's legal battle over their rival Covid-19 vaccines looks set to continue after London's High Court gave a mixed ruling on two of Moderna's patents, likely prompting a flurry of appeals in the London leg of the litigation.
1 Underwhelming Stat That May Have You Thinking Twice About Buying Pfizer's Stock
Market Chatter: Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits
A Delaware Superior Court judge rejected an appeal from GSK (GSK) and other drugmakers to overturn a ruling that cleared the way for over 70,000 lawsuits alleging that the heartburn drug Zantac causes
Cantor Fitzgerald Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $45
Cantor Fitzgerald analyst Louise Chen maintains $Pfizer(PFE.US)$ with a buy rating, and maintains the target price at $45.According to TipRanks data, the analyst has a success rate of 39.5% and a tota
Amazon Web Services Focuses On The Future, Anticipating AI Challenges Years In Advance To Deliver 'True Value' For Customers
Amazon.com Inc (NASDAQ:AMZN) is taking an all-encompassing approach to enterprise AI in an effort to better deliver the tools that customers need when they need them.What To Know: Monday on CNBC's "Cl
Pfizer Options Spot-On: On July 1st, 109K Contracts Were Traded, With 2.84 Million Open Interest
On July 1st ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 109K options for the day, of which put options accounted for 28.41% of the total transactions, and call opti
A Glimpse Into The Expert Outlook On Pfizer Through 9 Analysts
9 analysts have expressed a variety of opinions on Pfizer (NYSE:PFE) over the past quarter, offering a diverse set of opinions from bullish to bearish.The following table summarizes their recent ratin
Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target
Cantor Fitzgerald analyst Louise Chen reiterates Pfizer (NYSE:PFE) with a Overweight and maintains $45 price target.